PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ne ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...
The antisense oligonucleotides market offers growth opportunities across diverse disease indications, with promising ...
Agilent introduces the Altura Line of Inert HPLC Columns for superior results in biotherapeutic testing: Santa Clara, California Wednesday, October 1, 2025, 09:00 Hrs [IST] Agilen ...
September 30, 2025 -- VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, ...
Can you share some highlights from the BETTER study with us? Marion Munk, MD, PhD: I'm very excited about this project. We ...
Biogen Inc. (NASDAQ:BIIB) ranks among the most undervalued NASDAQ stocks to buy now. On September 18, Biogen Inc.
Oligonucleotide (oligo) therapies are gaining momentum due to their broad applications in diagnostics, therapeutics, research, and personalized medicine. These treatments offer precise, ...
TipRanks on MSN
PepGen Inc. Announces Public Offering Agreement
PepGen Inc. ( ($PEPG) ) just unveiled an update. On September 24, 2025, PepGen Inc. announced an underwriting agreement with Leerink Partners LLC ...
PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing ...
PepGen Inc. ( (PEPG) ) has issued an announcement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback